GlassScriptPhysician profile
Hailey A Brickman
NPI 1598315947
$81,993.44
in general payments reported to CMS, 2019-2025
33 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,276 · 2022: $6,413 · 2023: $20K · 2024: $12K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $18K · Travel and Lodging: $3,945 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29,184.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,250.00 |
| Consulting Fee | $17,563.00 |
| Travel and Lodging | $3,945.31 |
| Education | $362.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,065.58 | 2021-2025 | |
| Lilly USA, LLC | $18,961.29 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $6,413.12 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $6,036.11 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Medimetriks Pharmaceuticals, INC. | $3,750.00 | 2022-2023 | Neo-Synalar, Sumadan Wash |
| Regeneron Healthcare Solutions, INC. | $3,476.06 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $3,394.64 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $2,496.19 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $2,054.42 | 2021-2025 | |
| Janssen Biotech, INC. | $2,034.01 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,893.70 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $1,777.75 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $1,722.10 | 2021-2025 | |
| Pfizer INC. | $1,458.47 | 2021-2025 | |
| Amgen INC. | $1,455.49 | 2021-2025 | Otezla, Otezla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,109.78 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $975.48 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Journey Medical Corporation | $706.86 | 2021-2024 | |
| Botanix Sb INC | $622.42 | 2025 | Sofdra |
| Leo Pharma INC. | $620.65 | 2022-2025 | Adbry, Anzupgo |
| Epi Health, LLC | $369.97 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $352.78 | 2021-2025 | |
| Organon LLC | $252.41 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $199.40 | 2021-2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $172.47 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $158.86 | 2021 | |
| Merz North America, INC. | $133.42 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $101.83 | 2024-2025 | Valchlor |
| Almirall LLC | $70.05 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $64.24 | 2025 | Natroba, Spinosad |
| Allergan, INC. | $54.04 | 2021-2022 | |
| Fidia Pharma USA INC. | $23.86 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.99 | 2024 | Clear & Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Brickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.